ArticleBMC microbiology2019
Characterization of a bacteriophage with broad host range against strains of Pseudomonas aeruginosa isolated from domestic animals.
Article in BMC microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Pooled it
- Efficacy of lytic bacteriophages isolated from sewage-treatment plants in Mbarara district, Uganda against ciprofloxacin-resistant Salmonella Typhi in a mice infection model.BMC infectious diseases · 2026Article
- Isolation, characterization and genomic insights of the lytic bacteriophage TANUVAS_MVC-VPH-AB targeting Acinetobacter spp. with antibacterial and anti-biofilm activity.Molecular biology reports · 2026Article
- Phage cocktails containing a dual-receptorApplied and environmental microbiology · 2026Article
- Phage-antibiotic synergistic effect for treating cutaneous wounds infections caused by MRSA and the assessment of wound healing biomarkers in a rabbit model.Scientific reports · 2026Article
- Steering the course: targeting and exploiting surface receptors in phage therapy.Journal of bacteriology · 2026Review
- Targeting multidrug-resistant Escherichia coli by two isolated bacteriophages from hospital wastewater.Folia microbiologica · 2025Article
- Closed genome sequence of anMicrobiology resource announcements · 2025Article
- The C-terminus of the tail fiber protein of PB1-like phages is responsible for the host recognition.Virus genes · 2025Article
- Antimicrobial Potential of Bacteriophages JG005 and JG024 AgainstVeterinary sciences · 2025Article
- CRISPRi-mediated repression of threeJournal of bacteriology · 2025Article
- Characterization and purification of Pseudomonas aeruginosa phages for the treatment of canine infections.BMC microbiology · 2025Article
- Proliferative and viability effects of two cyanophages on freshwater bloom-forming species Microcystis aeruginosa and Raphidiopsis raciborskii vary between strains.Scientific reports · 2025Article
- Bacteriophages: A Challenge for Antimicrobial Therapy.Microorganisms · 2025Review
- Bacteriophage as an anti-biofilm agent against Pseudomonas aeruginosa from wound infection.PloS one · 2025Article
- Isolation, characterization and liposome-loaded encapsulation of a novel virulentFrontiers in microbiology · 2025Article
- Characterization and genomic analysis of PA-56Heliyon · 2024Article
- Development of the CRISPR-Cas12a system for editing ofiScience · 2024Article
- Review
- Isolation, Characterization, and Complete Genome Sequence of Escherichia Phage KIT06 Which Infects Nalidixic Acid-ResistantAntibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPseudomonas aeruginosa is an opportunistic pathogen and one of the leading causes of nosocomial infections. Moreover, the species can cause severe infections in cystic fibrosis patients, in burnt victims and cause disease in domestic animals. The control of these infections is often difficult due to its vast repertoire of mechanisms for antibiotic resistance. Phage therapy investigation with P. aeruginosa bacteriophages has aimed mainly the control of human diseases. In the present work, we have isolated and characterized a new bacteriophage, named Pseudomonas phage BrSP1, and investigated its host range against 36 P. aeruginosa strains isolated from diseased animals and against P. aeruginosa ATCC strain 27853.
resultsWe have isolated a Pseudomonas aeruginosa phage from sewage. We named this virus Pseudomonas phage BrSP1. Our electron microscopy analysis showed that phage BrSP1 had a long tail structure found in members of the order Caudovirales. "In vitro" biological assays demonstrated that phage BrSP1 was capable of maintaining the P. aeruginosa population at low levels for up to 12 h post-infection. However, bacterial growth resumed afterward and reached levels similar to non-treated samples at 24 h post-infection. Host range analysis showed that 51.4% of the bacterial strains investigated were susceptible to phage BrSP1 and efficiency of plating (EOP) investigation indicated that EOP values in the strains tested varied from 0.02 to 1.72. Analysis of the phage genome revealed that it was a double-stranded DNA virus with 66,189 bp, highly similar to the genomes of members of the genus Pbunavirus, a group of viruses also known as PB1-like viruses.
conclusionThe results of our "in vitro" bioassays and of our host range analysis suggested that Pseudomonas phage BrSP1 could be included in a phage cocktail to treat veterinary infections. Our EOP investigation confirmed that EOP values differ considerably among different bacterial strains. Comparisons of complete genome sequences indicated that phage BrSP1 is a novel species of the genus Pbunavirus. The complete genome of phage BrSP1 provides additional data that may help the broader understanding of pbunaviruses genome evolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.